Transplantation in the highly sensitized pediatric patient

Circulation

Volumn 129, Issue 22, 2014, Pages 2313-2319

  Castleberry, Chesney ^a   Ryan, Thomas D ^a   Chin, Clifford ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

antibody mediated rejection; complement system proteins; heart transplantation; HLA antigens

Indexed keywords

BORTEZOMIB; COMPLEMENT COMPONENT C1Q; COMPLEMENT FIXING ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ECULIZUMAB; HLA ANTIBODY; HLA ANTIGEN; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEASOME INHIBITOR; RITUXIMAB; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ANTIBODY DETECTION; ANTIBODY MEDIATED REJECTION; ANTIGEN ANTIBODY COMPLEX; ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE ACTIVATION; BLOOD; BLOOD GROUP ABO SYSTEM; BLOOD GROUP TYPING; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CELL POPULATION; CELL PROLIFERATION; CIRCULATION; CLINICAL DECISION MAKING; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CORONARY ARTERY VASCULOPATHY; EXTRACORPOREAL OXYGENATION; GRAFT DYSFUNCTION; GRAFT SURVIVAL; HEART FAILURE; HEART TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MONOTHERAPY; MULTIPLE MYELOMA; ORGAN DONOR; PEDIATRICS; PLASMAPHERESIS; PRE B LYMPHOCYTE; PREGNANCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SENSITIZATION; SURVIVAL; TISSUE GRAFT; TREATMENT OUTCOME; TREATMENT RESPONSE; VASCULAR DISEASE; VENTRICULAR ASSIST DEVICE;

ANTIBODY MEDIATED REJECTION; COMPLEMENT SYSTEM PROTEINS; HEART TRANSPLANTATION; HLA ANTIGENS;

ABO BLOOD-GROUP SYSTEM; ADOLESCENT; ANTIBODIES; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; GRAFT REJECTION; HEART TRANSPLANTATION; HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; PLASMAPHERESIS;

EID: 84901847192     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.001378     Document Type: Article

References (88)

1. Kantrowitz A, Haller JD, Joos H, Cerruti MM, Carstensen HE. Transplantation of the heart in an infant and an adult. Am J Cardiol. 1968;22:782-790.
2. Dipchand AI, Kirk R, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dobbels F, Lund LH, Rahmel AO, Yusen RD, Stehlik J; International Society for Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: sixteenth official pediatric heart transplantation report - 2013; focus theme: age. J Heart Lung Transplant. 2013;32:979-988.
3. Conrad SA, Rycus PT, Dalton H. Extracorporeal Life Support Registry report 2004. ASAIO J. 2005;51:4-10.
4. Warnecke H, Berdjis F, Hennig E, Lange P, Schmitt D, Hummel M, Hetzer R. Mechanical left ventricular support as a bridge to cardiac transplantation in childhood. Eur J Cardiothorac Surg. 1991;5:330-333.
5. Almond CS, Buchholz H, Massicotte P, Ichord R, Rosenthal DN, Uzark K, Jaquiss RD, Kroslowitz R, Kepler MB, Lobbestael A, Bellinger D, Blume ED, Fraser CD Jr, Bartlett RH, Thiagarajan R, Jenkins K. Berlin Heart EXCOR pediatric ventricular assist device Investigational Device Exemption study: study design and rationale. Am Heart J. 2011;162:425- 435.e6.
6. Fraser CD Jr, Jaquiss RD, Rosenthal DN, Humpl T, Canter CE, Blackstone EH, Naftel DC, Ichord RN, Bomgaars L, Tweddell JS, Massicotte MP, Turrentine MW, Cohen GA, Devaney EJ, Pearce FB, Carberry KE, Kroslowitz R, Almond CS; Berlin Heart Study Investigators. Prospective trial of a pediatric ventricular assist device. N Engl J Med. 2012;367:532-541.
7. Brand A. Immunological aspects of blood transfusions. Transpl Immunol. 2002;10:183-190.
8. Kirk R, Edwards LB, Aurora P, Taylor DO, Christie J, Dobbels F, Kucheryavaya AY, Rahmel AO, Hertz MI. Registry of the International Society for Heart and Lung Transplantation: eleventh official pediatric heart transplantation report - 2008. J Heart Lung Transplant. 2008;27:970-977.
9. Lietz K, John R, Kocher A, Schuster M, Mancini DM, Edwards NM, Itescu S. Increased prevalence of autoimmune phenomena and greater risk for alloreactivity in female heart transplant recipients. Circulation. 2001;104(suppl 1):I177-I183.
10. Massad MG, Cook DJ, Schmitt SK, Smedira NG, McCarthy JF, Vargo RL, McCarthy PM. Factors influencing HLA sensitization in implantable LVAD recipients. Ann Thorac Surg. 1997;64:1120-1125.
11. McKenna DH Jr, Eastlund T, Segall M, Noreen HJ, Park S. HLA alloimmunization in patients requiring ventricular assist device support. J Heart Lung Transplant. 2002;21:1218-1224.
12. Mehra MR, Uber PA, Uber WE, Scott RL, Park MH. Allosensitization in heart transplantation: implications and management strategies. Curr Opin Cardiol. 2003;18:153-158.
13. Ozdemir FN, Sezer S, Güz G, Arat Z, Turan M, Haberal M. Is hepatitis C virus infection a risk factor for panel-reactive antibody positivity? Transpl Int. 2000;13(suppl 1):S31-S33.
14. Rebibou JM, Chabod J, Alcalay D, Coussediere MC, Deteix P, Touchard G, Dupont I, Thévenin C, Chalopin JM, Tiberghien P. Flow cytometric evaluation of pregnancy-induced anti-HLA immunization and blood transfusion- induced reactivation. Transplantation. 2002;74:537-540.
15. Stringham JC, Bull DA, Fuller TC, Kfoury AG, Taylor DO, Renlund DG, Karwande SV. Avoidance of cellular blood product transfusions in LVAD recipients does not prevent HLA allosensitization. J Heart Lung Transplant. 1999;18:160-165.
16. Nwakanma LU, Williams JA, Weiss ES, Russell SD, Baumgartner WA, Conte JV. Influence of pretransplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era. Ann Thorac Surg. 2007;84:1556-1562.
17. Di Filippo S, Girnita A, Webber SA, Tsao S, Boyle GJ, Miller SA, Gandhi SK, Zeevi A. Impact of ELISA-detected anti-HLA antibodies on pediatric cardiac allograft outcome. Hum Immunol. 2005;66:513-518.
18. Shaddy RE, Hawkins JA. Immunology and failure of valved allografts in children. Ann Thorac Surg. 2002;74:1271-1275.
19. Shaddy RE, Thompson DD, Osborne KA, Hawkins JA, Fuller TC. Persistence of human leukocyte antigen (HLA) antibodies after one year in children receiving cryopreserved valved allografts. Am J Cardiol. 1997;80:358-359.
20. Breinholt JP 3rd, Hawkins JA, Lambert LM, Fuller TC, Profaizer T, Shaddy RE. A prospective analysis of the immunogenicity of cryopreserved nonvalved allografts used in pediatric heart surgery. Circulation. 2000;102(suppl 3):III179-III182.
21. Cochran RP, Kunzelman KS. Cryopreservation does not alter antigenic expression of aortic allografts. J Surg Res. 1989;46:597-599.
22. Gall KL, Smith SE, Willmette CA, O'Brien MF. Allograft heart valve viability and valve-processing variables. Ann Thorac Surg. 1998;65:1032-1038.
23. Hoekstra F, Witvliet M, Knoop C, Akkersdijk G, Jutte N, Bogers A, Claas F, Weimar W. Donor-specific anti-human leukocyte antigen class I antibodies after implantation of cardiac valve allografts. J Heart Lung Transplant. 1997;16:570-572.
24. Hoekstra FM, Witvliet M, Knoop CY, Wassenaar C, Bogers AJ, Weimar W, Claas FH. Immunogenic human leukocyte antigen class II antigens on human cardiac valves induce specific alloantibodies. Ann Thorac Surg. 1998;66:2022-2026.
25. Oei FB, Welters MJ, Knoop CJ, Vaessen LM, Stegmann AP, Weimar W, Bogers AJ. Circulating donor-specific cytotoxic T lymphocytes with high avidity for donor human leukocyte antigens in pediatric and adult cardiac allograft valved conduit recipients. Eur J Cardiothorac Surg. 2000;18:466-472.
26. Ross DN. Evolution of the homograft valve. Ann Thorac Surg. 1995;59:565-567.
27. Shaddy RE, Hunter DD, Osborn KA, Lambert LM, Minich LL, Hawkins JA, McGough EC, Fuller TC. Prospective analysis of HLA immunogenicity of cryopreserved valved allografts used in pediatric heart surgery. Circulation. 1996;94:1063-1067.
28. Smith JD, Ogino H, Hunt D, Laylor RM, Rose ML, Yacoub MH. Humoral immune response to human aortic valve homografts. Ann Thorac Surg. 1995;60:S127-S130.
29. Welters MJ, Oei FB, Vaessen LM, Stegmann AP, Bogers AJ, Weimar W. Increased numbers of circulating donor-specific T helper lymphocytes after human heart valve transplantation. Clin Exp Immunol. 2001;124:353-358.
30. Hammond EH, Yowell RL, Nunoda S, Menlove RL, Renlund DG, Bristow MR, Gay WA Jr, Jones KW, O'Connell JB. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. J Heart Transplant. 1989;8:430-443.
31. Casarez TW, Perens G, Williams RJ, Kutay E, Fishbein MC, Reed EF, Alejos JC, Levi DS. Humoral rejection in pediatric orthotopic heart transplantation. J Heart Lung Transplant. 2007;26:114-119.
32. Holt DB, Lublin DM, Phelan DL, Boslaugh SE, Gandhi SK, Huddleston CB, Saffitz JE, Canter CE. Mortality and morbidity in pre-sensitized pediatric heart transplant recipients with a positive donor crossmatch utilizing peri-operative plasmapheresis and cytolytic therapy. J Heart Lung Transplant. 2007;26:876-882.
33. Mahle WT, Tresler MA, Edens RE, Rusconi P, George JF, Naftel DC, Shaddy RE. Allosensitization and outcomes in pediatric heart transplantation. J Heart Lung Transplant. 2011;30:1221-1227.
34. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med. 1969;280:735-739.
35. Ho EK, Vasilescu ER, Vlad G, Marboe CC, Addonizio LJ, Suciu-Foca N. HLA antibodies in pediatric heart transplantation. Pediatr Transplant. 2011;15:458-464.
36. Gebel HM, Bray RA. Sensitization and sensitivity: defining the unsensitized patient. Transplantation. 2000;69:1370-1374.
37. Tambur AR, Bray RA, Takemoto SK, Mancini M, Costanzo MR, Kobashigawa JA, D'Amico CL, Kanter KR, Berg A, Vega JD, Smith AL, Roggero AL, Ortegel JW, Wilmoth-Hosey L, Cecka JM, Gebel HM. Flow cytometric detection of HLA-specific antibodies as a predictor of heart allograft rejection. Transplantation. 2000;70:1055-1059.
38. Chen G, Sequeira F, Tyan DB. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol. 2011;72:849-858.
39. Batal I, Zeevi A, Lunz JG 3rd, Aggarwal N, Shapiro R, Randhawa P, Girnita A. Antihuman leukocyte antigen-specific antibody strength determined by complement-dependent or solid-phase assays can predict positive donorspecific crossmatches. Arch Pathol Lab Med. 2010;134:1534-1540.
40. Kittleson M, Patel J, Reed E, Zhang Q, Cecka M, Stimpson E, Velleca A, Burch C, Kawano M, Davis S, Moriguchi J, Ardehali A, Kobashigawa J. Does MFI quantitation of circulating antibodies correlate with positive cytotoxicity? J Heart Lung Transplant. 2010;29:S152.
41. Zeevi A, Lunz J, Feingold B, Shullo M, Bermudez C, Teuteberg J, Webber S. Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients. J Heart Lung Transplant. 2013;32:98-105.
42. Scott V, Williams RJ, Levi DS. Outcomes of cardiac transplantation in highly sensitized pediatric patients. Pediatr Cardiol. 2011;32:615-620.
43. Rossano JW, Morales DL, Zafar F, Denfield SW, Kim JJ, Jefferies JL, Dreyer WJ. Impact of antibodies against human leukocyte antigens on long-term outcome in pediatric heart transplant patients: an analysis of the United Network for Organ Sharing database. J Thorac Cardiovasc Surg. 2010;140:694-699, 699.e1.
44. Wright EJ, Fiser WP, Edens RE, Frazier EA, Morrow WR, Imamura M, Jaquiss RD. Cardiac transplant outcomes in pediatric patients with preformed anti-human leukocyte antigen antibodies and/or positive retrospective crossmatch. J Heart Lung Transplant. 2007;26:1163-1169.
45. Chin C, Chen G, Sequeria F, Berry G, Siehr S, Bernstein D, Rosenthal D, Reinhartz O, Tyan D. Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J Heart Lung Transplant. 2011;30:158-163.
46. Zeevi A, Marrari M, Feingold B, Webber S, Duquesnoy RJ. Human leukocyte antigen epitope analysis to assess complement- and non-complementbinding donor-specific antibody repertoire in a pediatric heart transplant recipient. Hum Immunol. 2012;73:48-51.
47. Kobashigawa J, Mehra M, West L, Kerman R, George J, Rose M, Zeevi A, Reinsmoen N, Patel J, Reed EF. Report from a consensus conference on the sensitized patient awaiting heart transplantation. J Heart Lung Transplant. 2009;28:213-225.
48. Jordan SC, Vo A, Tyan D, Toyota M. Desensitization therapy with intravenous gammaglobulin (IVIG): applications in solid organ transplantation. Trans Am Clin Climatol Assoc. 2006;117:199-211.
49. Jordan SC, Vo AA, Peng A, Toyoda M, Tyan D. Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant. 2006;6:459-466.
50. Asante-Korang A, Jacobs JP, Ringewald J, Carapellucci J, Rosenberg K, McKenna D, McCormack J, Wilmot I, Gjeldum A, Lopez-Cepero M, Sleasman J. Management of children undergoing cardiac transplantation with high panel reactive antibodies. Cardiol Young. 2011;21(suppl 2):124-132.
51. Everly MJ, Terasaki PI. The state of therapy for removal of alloantibody producing plasma cells in transplantation. Semin Immunol. 2012;24:143-147.
52. Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Rike AH, Cardi M, Wadih G, Brown E, Tevar A, Woodle ES. Proteasome inhibition reduces donorspecific antibody levels. Transplant Proc. 2009;41:105-107.
53. Mulder A, Heidt S, Vergunst M, Roelen DL, Claas FH. Proteasome inhibition profoundly affects activated human B cells. Transplantation. 2013;95:1331-1337.
54. Hodge EE, Klingman LL, Koo AP, Nally J, Hobbs RE, Stewart RW, Cook DJ. Pretransplant removal of anti-HLA antibodies by plasmapheresis and continued suppression on cyclosporine-based therapy after heart-kidney transplant. Transplant Proc. 1994;26:2750-2751.
55. McIntyre JA, Higgins N, Britton R, Faucett S, Johnson S, Beckman D, Hormuth D, Fehrenbacher J, Halbrook H. Utilization of intravenous immunoglobulin to ameliorate alloantibodies in a highly sensitized patient with a cardiac assist device awaiting heart transplantation: fluorescenceactivated cell sorter analysis. Transplantation. 1996;62:691-693.
56. Itescu S, Burke E, Lietz K, John R, Mancini D, Michler R, Rose E, Oz M, Edwards N. Intravenous pulse administration of cyclophosphamide is an effective and safe treatment for sensitized cardiac allograft recipients. Circulation. 2002;105:1214-1219.
57. John R, Lietz K, Burke E, Ankersmit J, Mancini D, Suciu-Foca N, Edwards N, Rose E, Oz M, Itescu S. Intravenous immunoglobulin reduces anti- HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation. 1999;100(suppl):II229-II235.
58. Kobashigawa JA, Patel JK, Kittleson MM, Kawano MA, Kiyosaki KK, Davis SN, Moriguchi JD, Reed EF, Ardehali AA. The long-term outcome of treated sensitized patients who undergo heart transplantation. Clin Transplant. 2011;25:E61-E67.
59. Leech SH, Lopez-Cepero M, LeFor WM, DiChiara L, Weston M, Furukawa S, Macha M, Singhal A, Wald JW, Nikolaidis LA, McClurken JB, Bove AA. Management of the sensitized cardiac recipient: the use of plasmapheresis and intravenous immunoglobulin. Clin Transplant. 2006;20:476-484.
60. Pisani BA, Mullen GM, Malinowska K, Lawless CE, Mendez J, Silver MA, Radvany R, Robinson JA. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. J Heart Lung Transplant. 1999;18:701-706.
61. Balfour IC, Fiore A, Graff RJ, Knutsen AP. Use of rituximab to decrease panel-reactive antibodies. J Heart Lung Transplant. 2005;24:628-630.
62. Schumacher KR, Ramon DS, Kamoun M, Caruthers R, Gajarski RJ. HLA desensitization in pediatric heart transplant candidates: efficacy of rituximab and IVIg. J Heart Lung Transplant. 2012;31:1041-1042.
63. Patel J, Everly M, Chang D, Kittleson M, Reed E, Kobashigawa J. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation. J Heart Lung Transplant. 2011;30:1320-1326.
64. Jacobs JP, Quintessenza JA, Boucek RJ, Morell VO, Botero LM, Badhwar V, van Gelder HM, Asante-Korang A, McCormack J, Daicoff GR. Pediatric cardiac transplantation in children with high panel reactive antibody. Ann Thorac Surg. 2004;78:1703-1709.
65. Pollock-BarZiv SM, den Hollander N, Ngan B-Y, Kantor P, McCrindle B, Dipchand AI. Pediatric heart transplantation in human leukocyte antigensensitized patients. Circulation. 2007;116:I-172-178.
66. Daly KP, Chandler SF, Almond CS, Singh TP, Mah H, Milford E, Matte GS, Bastardi HJ, Mayer JE, Fynn-Thompson F, Blume ED. Antibody depletion for the treatment of crossmatch-positive pediatric heart transplant recipients. Pediatr Transplant. 2013;17:661-669.
67. Nath DS, Angaswamy N, Basha HI, Phelan D, Moazami N, Ewald GA, Mohanakumar T. Donor-specific antibodies to human leukocyte antigens are associated with and precede antibodies to major histocompatibility complex class I-related chain A in antibody-mediated rejection and cardiac allograft vasculopathy after human cardiac transplantation. Hum Immunol. 2010;71:1191-1196.
68. Hammond EH, Yowell RL, Price GD, Menlove RL, Olsen SL, O'Connell JB, Bristow MR, Doty DB, Millar RC, Karwande SV, Jones KW, Gay WA, Renlund DG. Vascular rejection and its relationship to allograft coronary artery disease. J Heart Lung Transplant. 1992;11(pt 2):S111-S119.
69. Michaels PJ, Espejo ML, Kobashigawa J, Alejos JC, Burch C, Takemoto S, Reed EF, Fishbein MC. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant. 2003;22:58-69.
70. Reed EF, Hong B, Ho E, Harris PE, Weinberger J, Suciu-Foca N. Monitoring of soluble HLA alloantigens and anti-HLA antibodies identifies heart allograft recipients at risk of transplant-associated coronary artery disease. Transplantation. 1996;61:566-572.
71. Rummler S, Maier K, Barz D. Therapeutic apheresis in transplantation medicine: experience with cardiac and lung transplantation in Jena. Atheroscler Suppl. 2013;14:33-38.
72. Jackups R Jr, Canter C, Sweet SC, Mohanakumar T, Morris GP. Measurement of donor-specific HLA antibodies following plasma exchange therapy predicts clinical outcome in pediatric heart and lung transplant recipients with antibody-mediated rejection. J Clin Apher. 2013;28:301-308.
73. Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Rike AH, Cardi M, Wadih G, Tevar A, Woodle ES. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation. 2008;86:1754-1761.
74. Woodle ES, Walsh RC, Alloway RR, Girnita A, Brailey P. Proteasome inhibitor therapy for antibody-mediated rejection. Pediatr Transplant. 2011;15:548-556.
75. Kannabhiran D, Everly MJ, Walker-McDermott JK, Tiongko S, Friedlander R, Putheti P, Sharma V, Dadhania D. Changes in IgG subclasses of donor specific anti-HLA antibodies following bortezomib-based therapy for antibody mediated rejection. Clin Transpl. 2012:229-235.
76. Diwan TS, Raghavaiah S, Burns JM, Kremers WK, Gloor JM, Stegall MD. The impact of proteasome inhibition on alloantibody-producing plasma cells in vivo. Transplantation. 2011;91:536-541.
77. Morrow WR, Frazier EA, Mahle WT, Harville TO, Pye SE, Knecht KR, Howard EL, Smith RN, Saylors RL, Garcia X, Jaquiss RD, Woodle ES. Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients. Transplantation. 2012;93:319-324.
78. González-Roncero F, Suñer M, Bernal G, Cabello V, Toro M, Pereira P, Angel Gentil M. Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports. Transplant Proc. 2012;44:2690-2694.
79. Stewart ZA, Collins TE, Schlueter AJ, Raife TI, Holanda DG, Nair R, Reed AI, Thomas CP. Case report: eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant. Transplant Proc. 2012;44:3033-3036.
80. Noone D, Al-Matrafi J, Tinckam K, Zipfel PF, Herzenberg AM, Thorner PS, Pluthero FG, Kahr WH, Filler G, Hebert D, Harvey E, Licht C. Antibody mediated rejection associated with complement factor H-related protein 3/1 deficiency successfully treated with eculizumab. Am J Transplant. 2012;12:2546-2553.
81. Lonze BE, Dagher NN, Simpkins CE, Locke JE, Singer AL, Segev DL, Zachary AA, Montgomery RA. Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access. Am J Transplant. 2010;10:2154-2160.
82. Stegall MD, Diwan T, Raghavaiah S, Cornell LD, Burns J, Dean PG, Cosio FG, Gandhi MJ, Kremers W, Gloor JM. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant. 2011;11:2405-2413.
83. Tambur AR, Pamboukian SV, Costanzo MR, Herrera ND, Dunlap S, Montpetit M, Heroux A. The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome. Transplantation. 2005;80:1019-1025.
84. Wu GW, Kobashigawa JA, Fishbein MC, Patel JK, Kittleson MM, Reed EF, Kiyosaki KK, Ardehali A. Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes. J Heart Lung Transplant. 2009;28:417-422.
85. Lietz K, John R, Burke E, Schuster M, Rogers TB, Suciu-Foca N, Mancini D, Itescu S. Immunoglobulin M-to-immunoglobulin G anti-human leukocyte antigen class II antibody switching in cardiac transplant recipients is associated with an increased risk of cellular rejection and coronary artery disease. Circulation. 2005;112:2468-2476.
86. Irving C, Carter V, Parry G, Hasan A, Kirk R. Donor-specific HLA antibodies in paediatric cardiac transplant recipients are associated with poor graft survival. Pediatr Transplant. 2011;15:193-197.
87. Xydas S, Yang JK, Burke EM, Chen JM, Addonizio LJ, Mital SR, Itescu S, Hsu DT, Lamour JM. Utility of post-transplant anti-HLA antibody measurements in pediatric cardiac transplant recipients. J Heart Lung Transplant. 2005;24:1289-1296.
88. Kobashigawa J, Crespo-Leiro MG, Ensminger SM, Reichenspurner H, Angelini A, Berry G, Burke M, Czer L, Hiemann N, Kfoury AG, Mancini D, Mohacsi P, Patel J, Pereira N, Platt JL, Reed EF, Reinsmoen N, Rodriguez ER, Rose ML, Russell SD, Starling R, Suciu-Foca N, Tallaj J, Taylor DO, Van Bakel A, West L, Zeevi A, Zuckermann A. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant. 2011;30:252-269.